STIGALL L. JEREMY 4

What Happened

• Jeremy Stigall, Chief Business Officer of ClearPoint Neuro, had 17,778 restricted stock units (RSUs) settle into 17,778 shares on March 6, 2026. To satisfy tax withholding, 6,913 of those shares were delivered back to the company at $10.00 per share (total value $69,130). Net shares issued to Stigall = 10,865. The RSU settlement is reported on a Form 4 filed March 10, 2026.

Key Details

• Transaction date: March 6, 2026; Form 4 filed March 10, 2026 (no indication of a late filing).
• Primary actions: RSU settlement (exercise/conversion of derivative, code M) — 17,778 shares acquired; tax withholding (code F) — 6,913 shares withheld and delivered to the company at $10.00/share for $69,130.
• Net shares received: 17,778 − 6,913 = 10,865 shares.
• Shares owned after transaction: not specified in the filing.
• Footnotes: F1 confirms these were scheduled RSU vesting settlements; F2 explains the 6,913 shares were surrendered to satisfy applicable tax withholding.

Context

• This is a routine RSU vesting and tax-withholding transaction (common for executive compensation). The acquisition price for the vested RSUs is listed as N/A because RSUs convert to shares upon vesting; withholding of shares to cover taxes is a standard disposition and does not necessarily signal a buy or sell intent in the market.